RedHill Biopharma (RDHL) Price to Earnings (2013 - 2023)

RedHill Biopharma (RDHL) has reported Price to Earnings for 11 consecutive years, with 31.53 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Price to Earnings fell 99.55% year-over-year to 31.53 in Q2 2023; TTM through Jun 2023 was 46.44, a 88.6% increase from a year earlier, with the FY2025 full-year figure at 35.45, up 81.79% from the prior year.
• Price to Earnings was 31.53 for Q2 2023 at RedHill Biopharma, up from 799.64 in the prior quarter.
• Over five years, Price to Earnings peaked at 35056.89 in Q3 2020 and troughed at 1230.97 in Q3 2022.
• A 5-year average of 12264.99 and a median of 11820.86 in 2019 frame the typical range for Price to Earnings.
• Across the five-year window, Price to Earnings surged 148.29% in 2019 and slumped 109.39% in 2022, its largest moves.
• Over 5 years, Price to Earnings stood at 18086.19 in 2019, then gained by 13.72% to 20567.25 in 2020, then plunged by 104.55% to 935.83 in 2021, then jumped by 86.67% to 124.71 in 2022, then surged by 125.28% to 31.53 in 2023.
• The last three Price to Earnings figures came in at 31.53 (Q2 2023), 799.64 (Q1 2023), and 124.71 (Q4 2022), per Business Quant data.